A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce ...
On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly ...
AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...
The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results